Durvalumab showed long and durable effects after chemoradiotherapy in stage III non-small cell lung cancer: results of the PACIFIC study.
作者信息
Uemura Takehiro, Hida Toyoaki
机构信息
Department of Thoracic Oncology, Aichi Cancer Center Hospital, Aichi, Japan.
出版信息
J Thorac Dis. 2018 Apr;10(Suppl 9):S1108-S1112. doi: 10.21037/jtd.2018.03.180.
Abstract
摘要
相似文献
1
Durvalumab showed long and durable effects after chemoradiotherapy in stage III non-small cell lung cancer: results of the PACIFIC study.度伐利尤单抗在III期非小细胞肺癌放化疗后显示出长期持久的疗效：PACIFIC研究结果
J Thorac Dis. 2018 Apr;10(Suppl 9):S1108-S1112. doi: 10.21037/jtd.2018.03.180.
2
Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria.根据 PACIFIC 研究标准，在临床实践中符合接受度伐利尤单抗巩固治疗条件的不可切除 III 期非小细胞肺癌患者。
Respir Investig. 2019 Sep;57(5):466-471. doi: 10.1016/j.resinv.2019.03.011. Epub 2019 May 16.
3
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.durvalumab 联合放化疗治疗不可切除 III 期非小细胞肺癌（PACIFIC）患者的报告结果：一项随机、对照、III 期临床研究。
Lancet Oncol. 2019 Dec;20(12):1670-1680. doi: 10.1016/S1470-2045(19)30519-4. Epub 2019 Oct 7.
4
Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.免疫检查点抑制剂联合放化疗治疗不可切除 III 期非小细胞肺癌。
Lung Cancer. 2019 Aug;134:259-267. doi: 10.1016/j.lungcan.2019.05.027. Epub 2019 May 29.
5
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.度伐利尤单抗化疗和放疗后用于 III 期非小细胞肺癌的总生存。
N Engl J Med. 2018 Dec 13;379(24):2342-2350. doi: 10.1056/NEJMoa1809697. Epub 2018 Sep 25.
6
Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer.度伐利尤单抗：一种用于不可手术切除的非小细胞肺癌的潜在维持治疗药物。
Cancer Manag Res. 2018 May 1;10:931-940. doi: 10.2147/CMAR.S148009. eCollection 2018.
7
Durvalumab Extends OS in NSCLC.度伐利尤单抗可延长非小细胞肺癌患者的总生存期。
Cancer Discov. 2018 Dec;8(12):OF5. doi: 10.1158/2159-8290.CD-NB2018-135. Epub 2018 Oct 16.
8
Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients.不可切除的 III 期非小细胞肺癌患者不符合 PACIFIC 试验条件。
Cancer Chemother Pharmacol. 2019 Aug;84(2):275-280. doi: 10.1007/s00280-019-03885-4. Epub 2019 Jun 14.
9
MEDI 4736 (durvalumab) in non-small cell lung cancer.MEDI 4736（度伐利尤单抗）用于非小细胞肺癌的治疗。
Expert Opin Biol Ther. 2017 Oct;17(10):1317-1323. doi: 10.1080/14712598.2017.1351939. Epub 2017 Jul 13.
10
Durvalumab for the treatment of non-small cell lung cancer.度伐利尤单抗治疗非小细胞肺癌。
Expert Rev Anticancer Ther. 2019 Dec;19(12):1009-1016. doi: 10.1080/14737140.2019.1699407. Epub 2019 Dec 3.
引用本文的文献
1
Real-world incidence and risk factors of pneumonitis in chemoradiation plus immune checkpoint inhibitors compared with chemoradiation alone in lung cancer: a retrospective cohort study.与单纯放化疗相比，放化疗联合免疫检查点抑制剂治疗肺癌时肺炎的真实世界发病率及危险因素：一项回顾性队列研究
Transl Lung Cancer Res. 2024 Jan 31;13(1):139-151. doi: 10.21037/tlcr-23-756. Epub 2024 Jan 12.
2
Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer.循环肿瘤细胞与游离DNA整合在非小细胞肺癌中的预后价值
Heliyon. 2022 Jul 19;8(7):e09971. doi: 10.1016/j.heliyon.2022.e09971. eCollection 2022 Jul.
3
Durvalumab as Consolidation Therapy in Post-Multimodal Interventional Treatment for Patients with Advanced Solid Tumors: A Preliminary Study.度伐利尤单抗作为晚期实体瘤患者多模式介入治疗后巩固治疗的初步研究
J Oncol. 2022 Mar 15;2022:7794840. doi: 10.1155/2022/7794840. eCollection 2022.
4
Management of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer.非小细胞肺癌患者免疫相关不良事件的管理
Front Oncol. 2021 Sep 30;11:720759. doi: 10.3389/fonc.2021.720759. eCollection 2021.
5
Current Progress and Future Perspectives of Immune Checkpoint Inhibitors in Biliary Tract Cancer.免疫检查点抑制剂在胆管癌中的当前进展与未来展望
Onco Targets Ther. 2021 Mar 12;14:1873-1882. doi: 10.2147/OTT.S269671. eCollection 2021.
6
Imperfect Predictors for Lung Cancer Immunotherapy-A Field for Further Research.肺癌免疫治疗的不完美预测指标——一个有待进一步研究的领域。
Front Oncol. 2020 Nov 30;10:568174. doi: 10.3389/fonc.2020.568174. eCollection 2020.
7
Treatment of stage III non-small cell lung cancer in the era of immunotherapy: pathological complete response to neoadjuvant pembrolizumab and chemotherapy.免疫治疗时代III期非小细胞肺癌的治疗：新辅助帕博利珠单抗联合化疗后的病理完全缓解
Transl Lung Cancer Res. 2020 Oct;9(5):2059-2073. doi: 10.21037/tlcr-20-896.
8
Efficacy and safety of recombinant human endostatin combined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer: a pooled analysis.重组人内皮抑素联合放疗或放化疗治疗局部晚期非小细胞肺癌患者的疗效与安全性：一项汇总分析
Radiat Oncol. 2020 Aug 24;15(1):205. doi: 10.1186/s13014-020-01646-9.
9
Soluble immune checkpoint molecules: Serum markers for cancer diagnosis and prognosis.可溶性免疫检查点分子：癌症诊断和预后的血清标志物。
Cancer Rep (Hoboken). 2019 Aug;2(4):e1160. doi: 10.1002/cnr2.1160. Epub 2019 Feb 7.
10
Survival score to characterize prognosis in inoperable stage III NSCLC after chemoradiotherapy.用于表征不可切除的 III 期非小细胞肺癌放化疗后预后的生存评分。
Transl Lung Cancer Res. 2019 Oct;8(5):593-604. doi: 10.21037/tlcr.2019.09.19.
本文引用的文献
1
Cancer statistics, 2018.癌症统计数据，2018 年。
CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.
2
DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells.DNA 双链断裂修复途径调控癌细胞中 PD-L1 的表达。
Nat Commun. 2017 Nov 24;8(1):1751. doi: 10.1038/s41467-017-01883-9.
3
Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature.比较 PD-1 与 PD-L1 抑制剂在非小细胞肺癌中的毒性特征：文献系统分析。
Cancer. 2018 Jan 15;124(2):271-277. doi: 10.1002/cncr.31043. Epub 2017 Sep 28.
4
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.Durvalumab 用于 III 期非小细胞肺癌放化疗后的治疗。
N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8.
5
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.既往放疗与帕博利珠单抗治疗非小细胞肺癌的临床活性及毒性：KEYNOTE-001 1期试验的二次分析
Lancet Oncol. 2017 Jul;18(7):895-903. doi: 10.1016/S1470-2045(17)30380-7. Epub 2017 May 24.
6
Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.非小细胞肺癌中使用程序性死亡1和程序性死亡配体1抑制剂后肺炎的发生率：试验的系统评价和荟萃分析
Chest. 2017 Aug;152(2):271-281. doi: 10.1016/j.chest.2017.04.177. Epub 2017 May 10.
7
Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer.替西莫肽作为免疫疗法用于日本不可切除的III期非小细胞肺癌患者的I/II期研究。
Lung Cancer. 2017 Mar;105:23-30. doi: 10.1016/j.lungcan.2017.01.007. Epub 2017 Jan 17.
8
Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial.依托泊苷和顺铂与紫杉醇和卡铂联合同期胸部放疗治疗不可切除的 III 期非小细胞肺癌：一项多中心随机 III 期试验。
Ann Oncol. 2017 Apr 1;28(4):777-783. doi: 10.1093/annonc/mdx009.
9
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.阿特珠单抗对比多西他赛用于既往治疗过的非小细胞肺癌患者（OAK）：一项3期、开放标签、多中心随机对照试验
Lancet. 2017 Jan 21;389(10066):255-265. doi: 10.1016/S0140-6736(16)32517-X. Epub 2016 Dec 13.
10
Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis.《转移性 EGFR 突变非小细胞肺癌中免疫检查点抑制剂的Meta 分析》
J Thorac Oncol. 2017 Feb;12(2):403-407. doi: 10.1016/j.jtho.2016.10.007. Epub 2016 Oct 17.
Zotero 插件